<code id='24044D6FC5'></code><style id='24044D6FC5'></style>
    • <acronym id='24044D6FC5'></acronym>
      <center id='24044D6FC5'><center id='24044D6FC5'><tfoot id='24044D6FC5'></tfoot></center><abbr id='24044D6FC5'><dir id='24044D6FC5'><tfoot id='24044D6FC5'></tfoot><noframes id='24044D6FC5'>

    • <optgroup id='24044D6FC5'><strike id='24044D6FC5'><sup id='24044D6FC5'></sup></strike><code id='24044D6FC5'></code></optgroup>
        1. <b id='24044D6FC5'><label id='24044D6FC5'><select id='24044D6FC5'><dt id='24044D6FC5'><span id='24044D6FC5'></span></dt></select></label></b><u id='24044D6FC5'></u>
          <i id='24044D6FC5'><strike id='24044D6FC5'><tt id='24044D6FC5'><pre id='24044D6FC5'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:entertainment    - browse:9
          Adobe

          LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday. 

          The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired. 

          advertisement

          Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia